Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Journal of clinical endocrinology and metabolism
- Publicado em
- 19 abr 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
Lars Sävendahl, Tadej Battelino, Michael Højby Rasmussen, Meryl Brod, Paul Saenger, Reiko Horikawa
Descritores MeSH
- Dwarfism, Pituitary
- Human Growth Hormone
- Pituitary Hormones, Anterior
- Humans
- Insulin-Like Growth Factor I
- Mannitol
- Growth Hormone
- Body Height
- Phenol
- Child
Veja também
Estudos relacionados
- Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency
- Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
- Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4
- Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial